Search
Oxaliplatin
go.drugbank.com/drugs/DB00526ApprovedInvestigational[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. … [A797] Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics.
Milsaperidone
go.drugbank.com/drugs/DB24348ApprovedInvestigational[A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … [L56056] Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalIt is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesVayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. … A slow response time of 12 weeks is an impediment to successful management of ADHD as only 41.6% of subjects prescribed Vayarin remained compliant for the duration of the study.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersPipradrol
go.drugbank.com/drugs/DB11584ApprovedWithdrawnPipradrol (Meratran) [L2523] was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international
Naloxone
go.drugbank.com/drugs/DB01183ApprovedInvestigationalVet approvedDue to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. … However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal
Mixtures: TILIDIN 100/8 RETARD 1A PH, TILIDIN 100/8 RETARD 1A PHCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesNalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Lutropin alfa
go.drugbank.com/drugs/DB00044ApprovedInvestigationalIts pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum.
Mixtures: PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 3 ADETProducts: LUVERIS 75 IU, LUVERIS FOR INJECTION 75 iu/vial (Revised formula)Aluminum chlorohydrex propylene glycol
go.drugbank.com/drugs/DB11208ApprovedAluminum chlorohydrex propylene glycol is a complex consisting of Aluminum Chorohydrate and propylene glycol (PG). … It is an antiperspirant active ingredient found in antiperspirant drug products for over-the-counter human use.